Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bosco & Crossy's stock picks,talk area -- Ignore unavailable to you. Want to Upgrade?

To: yassinzineb who wrote (12962)	10/3/2005 9:53:42 AM
From: Crossy	Read Replies (1) \| Respond to of 37387

re: MEMY yassinzineb, thanks alot for the background story on MEMY. Being a biotech, it's outside of my personal range of interest at the moment but I do appreciate your summary - the company is credible and I got one more ticker for my biotech stable that I'm going to look up one day. I'm sure other threadsters share this appreciation ! rgrds CROSSY

To: yassinzineb who wrote (12962)	10/17/2005 9:12:52 AM
From: yassinzineb	Respond to of 37387

MEMY,Major announcement today Pact with Amgen biz.yahoo.com Memory Pharma Enters Pact With Amgen Monday October 17, 8:48 am ET Memory Pharmaceuticals to Get $5 Million in Collaboration With Amgen to Develop PDE10 Inhibitors MONTVALE, N.J. (AP) -- Drug developer Memory Pharmaceuticals Corp. said Friday that it will receive a $5 million payment from biotech company Amgen Inc. in a collaboration to develop compounds that inhibit an enzyme present in neurological disorders. Memory shares jumped 61 cents, or 22.5 percent, to $3.32 in premarket activity. Shares have traded between $1.75 and $7.08 over the past 52 weeks. Under the agreement, Memory could also receive milestone payments and royalties for products arising from the collaboration. The company said it also stands to get about $5.1 million in research funding over the next two years out of the agreement. The companies hope to develop drugs that inhibit PDE10, an enzyme that breaks down the chemical messengers cyclic adenosine monophosphate and cyclic guanosine monophosphate, which are both necessary for improving the performance of cells in the body, particularly nerve cells. High levels of PDE10 are found in the nerve cells of patients with neurological and psychiatric disorders. Memory has shown that PDE10 inhibitors work in animals thus far. The company posted revenue of $9.8 million in 2004.